ライフサイエンスコーパス: pharmacogenomics

1 ic basis of disease and drug response (i.e., pharmacogenomics).

2 interventions and assessing cancer risk and pharmacogenomics.

3 l applications in both genetic screening and pharmacogenomics.

4 genetic profiling studies), and host-related pharmacogenomics.

5 ll molecules and have clear implications for pharmacogenomics.

6 ic gene variants for medical diagnostics and pharmacogenomics.

7 genetic information, an application known as pharmacogenomics.

8 ed to prescription databases to advance ADHD pharmacogenomics.

9 inborn errors of metabolism in newborns and pharmacogenomics.

10 ude genomic factors, an area of study called pharmacogenomics.

11 d have broader impacts for drug response and pharmacogenomics.

12 es, highlighting the benefits of pre-emptive pharmacogenomics.

13 treatable disease in newborns and actionable pharmacogenomics.

14 nge is how to use these data effectively for pharmacogenomics.

15 functional approaches and model systems, and pharmacogenomics.

16 atabase with direct implications in clinical pharmacogenomics.

17 odules, with direct implications to clinical pharmacogenomics.

18 ing the realization of the full potential of pharmacogenomics.

19 impact and evolving evidence for clopidogrel pharmacogenomics.

20 at remain for the clinical implementation of pharmacogenomics.

21 o be important in disease susceptibility and pharmacogenomics.

22 n-induced pluripotent stem cells and systems pharmacogenomics accelerate future studies of precision

23 Pharmacogenomics addresses this issue by seeking to iden

24 an application of functional neuroimaging in pharmacogenomics and extend basic evidence of an inverte

25 A review of pharmacogenomics and how it affects the response to anal

26 wledge embedded in vast amounts of available pharmacogenomics and omics data.

27 developments in the field of cardiovascular pharmacogenomics and personalized medicine.

28 In the future, pharmacogenomics and point-of-care testing will likely p

29 Data from the Pharmacogenomics and Risk of Cardiovascular Disease (PAR

30 We discuss the implications for pharmacogenomics and the uncharted complexity in genotyp

31 is review will focus on pharmacogenetics and pharmacogenomics and their role in reducing ADRs, especi

32 level, the relationship between transporter pharmacogenomics and therapeutics in the age of individu

33 sed test to a sequencing study in anticancer pharmacogenomics and uncovered mechanistic insights into

34 fficiency may have important consequences in pharmacogenomics and variable drug toxicity observed in

35 ociation between genetics and drug response (pharmacogenomics) and the association of sequence variat

36 ical diagnostics, patient stratification for pharmacogenomics, and advanced forensic analysis.

37 ciation studies (GWAS), population genetics, pharmacogenomics, and cancer research.

38 ase-causing variants, cardiovascular-related pharmacogenomics, and carrier status for recessive disea

39 tion based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care.

40 and offer new approaches in systems biology, pharmacogenomics, and translational medicine.

41 with experimental medications in humans; the pharmacogenomics applied to these medications and disord

42 s of existing drugs, of potential utility in pharmacogenomics approaches (matching patients to medica

43 ntial utility in patient stratification, and pharmacogenomics approaches.

44 Systems pharmacology and pharmacogenomics are emerging to exploit the available d

45 Genomics and pharmacogenomics are signalling the start of a new era f

46 e, these technologies enable advancements in pharmacogenomics, as well as the identification of novel

47 Pharmacogenomics attempts to elucidate the inherited bas

48 ic strategies, particularly patient-specific pharmacogenomics-based therapy, with monitoring of thera

49 nerabilities and prioritization of potential pharmacogenomics biomarkers for development of personali

50 ntify potential network-based diagnostic and pharmacogenomics biomarkers from large-scale scRNA-seq p

51 dual patients' scRNA-seq data can be used as pharmacogenomics biomarkers to predict drug responses (T

52 ts leading mostly to monogenic disorders and pharmacogenomics biomarkers.

53 ut microenvironment, gut-brain interactions, pharmacogenomics, biopsychosocial, gender and cross cult

54 We cover the practical applications of pharmacogenomics both in the pharmaceutical industry and

55 Pharmacogenomics can also be used in a broader sense for

56 In drug discovery, pharmacogenomics can be used to aid lead identification,

57 namic properties of pharmacological systems, pharmacogenomics can now provide an objective measure of

58 as a foundation for further research on how pharmacogenomics can reduce the incidence of adverse rea

59 A pharmacogenomics characterization of mithramycin-induced

60 We applied the Pharmacogenomics Clinical Annotation Tool (PharmCAT) on

61 nt of epilepsy, epigenetic determinants, and pharmacogenomics comes the hope for better, disease-modi

62 s global participation and feedback from the pharmacogenomics community to promote the adoption of CP

63 e publicly available International Tamoxifen Pharmacogenomics Consortium (ITPC) dataset.

64 tudy (GWAS) in the AA International Warfarin Pharmacogenomics Consortium (IWPC) cohort (n = 340).

65 URPOSE To explore whether population-related pharmacogenomics contribute to differences in patient ou

66 Pharmacogenomics could optimize antipsychotic treatment

67 we report the integration of multi-omics and pharmacogenomics data across large-scale patient samples

68 a (CCLE) study as the benchmark dataset, all pharmacogenomics data exhibited their roles in inferring

69 based on integration of the heterogeneously pharmacogenomics data from both cell and drug sides.

70 Computational analysis of cancer pharmacogenomics data has resulted in biomarkers predict

71 ach topic, we summarize current genomics and pharmacogenomics data resources such as pan-cancer genom

72 integrative analysis of preclinical in vivo pharmacogenomics data to identify biomarkers predictive

73 By analyzing existing pharmacogenomics data, we propose the potential design o

74 acterize and learn from rapidly accumulating pharmacogenomics data.

75 igating the correspondence between different pharmacogenomics databases and discuss the potential fac

76 We demonstrate how to integrate pharmacogenomics databases through integration of the bi

77 ried disease-specific mutation databases and pharmacogenomics databases to identify genes and mutatio

78 Samples collected in pharmacogenomics databases typically belong to various c

79 mation is currently distributed over several pharmacogenomics databases.

80 Validation using simulated datasets and real pharmacogenomics datasets demonstrates the effectiveness

81 PharmacoDB integrates multiple cancer pharmacogenomics datasets profiling approved and investi

82 PharmacoDB 2.0 is a valuable tool for mining pharmacogenomics datasets, comparing and assessing drug-

83 y and standardization to accommodate growing pharmacogenomics datasets.

84 ients is very challenging; thus, most cancer pharmacogenomics discovery is conducted in preclinical s

85 to review the state of research on metformin pharmacogenomics, discuss the scientific and clinical hu

86 ses, dermatology, clinical pharmacology, and pharmacogenomics discussed the current state of drug all

87 t for therapies based on molecular genetics (pharmacogenomics, DNA microarrays, etc.) drives pharmace

88 The "omics"-genomics, pharmacogenomics, epigenomics, proteomics, metabolomics,

89 RECENT FINDINGS: As the field of pharmacogenomics expands, more and more candidate genes

90 is of immediate use for prioritizing cancer pharmacogenomics experiments, and recovers known clinica

91 The field of pharmacogenomics explores the influence of these genetic

92 dult-onset disease risk, carrier status, and pharmacogenomics findings from nGS of 159 newborns in th

93 The rapidly expanding field of pharmacogenomics focuses on the genetic contributions to

94 iomics has emerged as a natural extension of pharmacogenomics for studying variations in drug respons

95 t the opportunities for drug repurposing and pharmacogenomics for the treatment of hypertension.

96 In the case of pharmacogenomics, for instance, variants of consequence

97 epigenetics, gene-environment interactions, pharmacogenomics, genetic counseling, and ethical and so

98 understanding of cellular protein complexes, pharmacogenomics, genetic diagnosis and gene therapies.

99 We address the relevance of epigenetics, pharmacogenomics, genetic testing and counseling, and th

100 Pharmacogenomics has employed candidate gene studies and

101 However, pharmacogenomics has made only a few inroads into clinic

102 The field of pharmacogenomics has seen some exciting advances in the

103 Pharmacogenetics and, more recently, pharmacogenomics have been applied to the field of ADRs

104 Precision medicine, including multiomics and pharmacogenomics, hold promise to enhance understanding

105 Pharmacogenomics holds great promise for the development

106 to leukemogenesis, drug resistance, and host pharmacogenomics, identified novel subtypes of leukemia,

107 Important associations of pharmacogenomics in cardiovascular medicine include clop

108 (n = 5903) participating in the multi-ethnic Pharmacogenomics in Childhood Asthma (PiCA) consortium.

109 olizing enzymes, genetic susceptibility, and pharmacogenomics in determining cardiovascular disease r

110 review will discuss recent investigations of pharmacogenomics in heart failure, and the challenge of

111 udy was conducted to investigate the role of pharmacogenomics in NCPH in HIV patients with prior dida

112 ay for clinical studies assessing the use of pharmacogenomics in the clinical management of patients

113 ways coupled with a massive knowledge gap in pharmacogenomics in the health-care workforce.

114 the prospective study of population-related pharmacogenomics in which ethnic differences in antineop

115 Last, we were also able to provide pharmacogenomics information based on CYP2D6 genotype da

116 ailable and decreasing in cost, implementing pharmacogenomics into clinical practice - widely regarde

117 d the first steps towards the integration of pharmacogenomics into clinical practice.

118 e polymorphism association studies in muscle pharmacogenomics is a field of expected future growth.

119 Nevertheless, the importance of pharmacogenomics is likely to increase as the cost of dr

120 The impact of host pharmacogenomics is outlined.

121 The promise of pharmacogenomics is that it will one day result in targe

122 Pharmacogenomics is the study of how human genetic infor

123 Pharmacogenomics is the study of the inherited basis of

124 One of the goals of pharmacogenomics is the use of genetic variants to predi

125 Because one of the goals of pharmacogenomics is to identify individuals and target p

126 The goal of the emerging discipline of pharmacogenomics is to personalize therapy based on an i

127 Knowledge in pharmacogenomics is typically composed of units that hav

128 The behavioural impact of pharmacogenomics is untested.

129 This field, called pharmacogenomics, is a key area in the development of pr

130 Through increased knowledge in the area of pharmacogenomics, it is hoped that that treatment of pai

131 named kinome-wide network module for cancer pharmacogenomics (KNMPx), for identifying actionable mut

132 s and phenotype frequencies aligned with the Pharmacogenomics Knowledge Base, although notable popula

133 ncies are disseminated via the PharmGKB (The Pharmacogenomics Knowledgebase: ).

134 Pharmacogenomics may alter prescribing in a further 41%.

135 rs, biomarkers, advanced cardiac imaging and pharmacogenomics may be used to classify patients at ris

136 spective study was performed by the Canadian Pharmacogenomics Network for Drug Safety using patients

137 n's Hospital, Memphis, TN) who discussed the pharmacogenomics of acute lymphoblastic leukemia as a ca

138 The discovery cohort (Pharmacogenomics of Adrenal Suppression with Inhaled Cor

139 elet therapy in individuals (n=565) from the Pharmacogenomics of Anti-Platelet Intervention (PAPI) St

140 sease (epilepsy), genomics of drug response (pharmacogenomics of antiepileptic drugs) and genomics of

141 DESIGN, SETTING, AND PARTICIPANTS: In the Pharmacogenomics of Antiplatelet Intervention (PAPI) Stu

142 last year that address the pathogenesis and pharmacogenomics of asthma.

143 o model basic tumor biology and to study the pharmacogenomics of BCa.

144 An initial Pharmacogenomics of Bipolar Disorder study (PGBD) GWAS o

145 ct of buprenorphine treatment, including the pharmacogenomics of buprenorphine response and treatment

146 could be due to differences in AE reported, pharmacogenomics of drug metabolism/disposition, total d

147 The pharmacogenomics of treatment response encapsulates both

148 gations of minimal residual disease and host pharmacogenomics, offer promising avenues of research.

149 expression), response to treatment, and host pharmacogenomics offers the potential to enhance or supp

150 icacy of ADT, establishing the importance of pharmacogenomics on individual's response to this therap

151 Our results suggest that using pharmacogenomics parameters to tailor induction regimens

152 ern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a large

153 orms other mtPRS methods in both disease and pharmacogenomics (PGx) genome-wide association studies (

154 ate the scale of potential ADR mitigation by pharmacogenomics (PGx) implementation.

155 Pharmacogenomics (PGx) is an integral part of precision

156 Pharmacogenomics (PGx) is the concept that treatments ca

157 tudy, we leveraged PharmGKB, a comprehensive pharmacogenomics (PGx) knowledgebase, to formulate a ter

158 Pharmacogenomics (PGx) research holds the promise for de

159 ion study (GWAS) directly to a corresponding pharmacogenomics (PGx) setting.

160 Applying PRSs to pharmacogenomics (PGx) studies has begun to show great p

161 Pharmacogenomics (PGx) studies how genomic variations im

162 Pharmacogenomics (PGx), the study of inherited genomic v

163 lypharmacology of dipyridamole, we focus our pharmacogenomics pipeline on mevalonate pathway genes, w

164 ng this knowledge, we develop an integrative pharmacogenomics pipeline to identify compounds similar

165 ion, it highlights the evolving landscape of pharmacogenomics, polygenic risk scores, and precision p

166 ccurate local ancestry analysis in genetics, pharmacogenomics, population genetics, and clinical diag

167 By analyzing drug pharmacogenomics profiles from the Genomics of Drug Sens

168 SpaRx transfers the knowledge from pharmacogenomics profiles to single-cell spatial transcr

169 ctronic Medical Records and Genomics Network Pharmacogenomics project from 7 US academic medical cent

170 omics, structural genomics, transcriptomics, pharmacogenomics, proteomics and metabolomics, allows fo

171 Pharmacogenomics provides the potential to unveil herita

172 ere to assess the feasibility of prospective pharmacogenomics research in multicenter international c

173 The Pharmacogenomics Research Network and the Clinical Pharm

174 We used a pharmacometabolomics-informed pharmacogenomics research strategy to identify genes ass

175 Less attention has been paid to psychiatric pharmacogenomics research, despite its potential to deli

176 We support community-based pharmacogenomics research, inclusive of Indigenous value

177 ican Americans (AAs) are underrepresented in pharmacogenomics research, which has led to a significan

178 iew describes some of the recent advances in pharmacogenomics research.

179 llMiner and CellMinerCDB and is an important pharmacogenomics resource for the field.

180 f state-of-the-art DL methods and up-to-date pharmacogenomics resources and future opportunities and

181 rapy in 768 hypertensive participants in the Pharmacogenomics Responses of Antihypertensive Responses

182 enabling resources for the nascent field of pharmacogenomics (see Glossary), which tests the idea th

183 The field of pharmacogenomics seeks to identify genetic factors that

184 ega-3 fatty acids), providing a means toward pharmacogenomics stratification of patients and monitori

185 tablish a generalizable method for exploring pharmacogenomics, structure and function across broad cl

186 Pharmacogenomics studies are attracting an increasing am

187 Here, we summarize the recent pharmacogenomics studies in immunotherapy responsiveness

188 Cancer pharmacogenomics studies provide valuable insights into

189 This comprehensive pharmacogenomics study showed that individuals with the

190 ate chemosensitivity data from a large-scale pharmacogenomics study with basal gene expression data f

191 le tests, and investigation of other uses of pharmacogenomics, such as estimating the likelihood of r

192 ing, personalized patient selection based on pharmacogenomics, systemic versus intramural cell delive

193 Common and classic features of pharmacogenomics that are related to both antiretroviral

194 utine sample storage and processing has made pharmacogenomics the most widely applied discovery-based

195 esent distinct opportunities for psychiatric pharmacogenomics to enter a new and productive phase of

196 colleagues took a different approach: using pharmacogenomics to focus on neural stem cell lineage, t

197 PMT polymorphism illustrate the potential of pharmacogenomics to optimize cancer therapy by avoiding

198 Advances in the clinical application of pharmacogenomics to predict response to oncology therape

199 HIV and cancer medicine have used pharmacogenomics to some extent in clinical care.

200 genotyping may be required to define cancer pharmacogenomics unequivocally.

201 Carrier status for recessive diseases and pharmacogenomics variants were reported in 88% and 5% of

202 Pharmacogenomics will have an increasing role in the tre

203 rogress in the field of pharmacogenetics and pharmacogenomics will help further our understanding of

204 A better understanding of pharmacogenomics will optimize the current treatment sel

205 By resolving these hurdles, pharmacogenomics will yield significant, but incremental

206 germline genetics analysis methods to cancer pharmacogenomics with a focus on the special considerati

207 with a focus on monogenetic traits to become pharmacogenomics, with a genome-wide perspective.